ライフサイエンスコーパス: uterine cancer

1 al cancer subtypes, including PTEN-deficient uterine cancer.

2 vanced age was the strongest risk factor for uterine cancer.

3 t and progression of the most common type of uterine cancer.

4 omy for recurrence after surgical staging of uterine cancer.

5 formation for decision making for women with uterine cancer.

6 imaging to determine the anatomic origin of uterine cancer.

7 ogy and Obstetrics (FIGO) staging system for uterine cancer.

8 rotomy for comprehensive surgical staging of uterine cancer.

9 y the association between clomiphene use and uterine cancer.

10 equently inactivated in brain, prostate, and uterine cancer.

11 s in prostate cancer, testicular cancer, and uterine cancer.

12 and bladder, lung, pancreatic, prostate, and uterine cancers.

13 may be a useful marker for aggressive human uterine cancers.

14 eatly disproportionate amount of deaths from uterine cancers.

15 endometrial cancer, 1 case of nonendometrial uterine cancer, 13 cases of cervical cancer, and 7 cases

16 The risk of uterine cancer (42%) exceeded that for colorectal cancer

17 7878 due to pancreatic cancer; 209314 due to uterine cancer; 421628 due to kidney cancer; 487518 due

18 and Relevance: Although the overall risk for uterine cancer after RRSO was not increased, the risk fo

19 Objective: To determine the risk for uterine cancer and distribution of specific histologic s

20 have less cardiovascular disease, breast and uterine cancer and menopausal symptoms than those eating

21 The occurrence of uterine cancer and precancerous uterine lesions was dete

22 seful for determining the anatomic origin of uterine cancer and provides helpful information regardin

23 ess radiotherapy for breast, colorectal, and uterine cancers and fewer chemotherapy sessions.

24 trogen-related toxicities such as breast and uterine cancer are mediated through ERalpha.

25 n; and the incidence of breast, ovarian, and uterine cancer are not available.

26 requently develops benign fibroid tumors but uterine cancers are relatively rare.

27 leeding caused by endometrial hyperplasia or uterine cancer as a result of prolonged exposure to tumo

28 ovarian cancer mortality (OR = 1.5), and 3) uterine cancer as a risk factor for pancreatic cancer mo

29 ith a confirmed histopathologic diagnosis of uterine cancer between April 1, 2000, and March 31, 2009

30 as been identified as a potent suppressor of uterine cancer, but the biological modes of action of LK

31 and contributes to the pathogenesis of human uterine cancer by activating COX-2 expression.

32 in MCF-7 breast adenocarcinoma and Ishikawa uterine cancer cell lines.

33 g either HMGA1a or COX-2 in high-grade human uterine cancer cells blocks anchorage-independent cell g

34 inds directly to the COX-2 promoter in human uterine cancer cells in vivo and activates its expressio

35 Censoring occurred at uterine cancer diagnosis, hysterectomy, last follow-up,

36 of the involved ovary and that a concomitant uterine cancer has been excluded.

37 ons may explain in part the reduced rates of uterine cancer in Asian countries compared with those in

38 Laparoscopic surgical staging for uterine cancer is feasible and safe in terms of short-te

39 ted that laparoscopic surgical management of uterine cancer is superior for short-term safety and len

40 Uterine cancer is the most common cancer of the female g

41 ortance: The link between BRCA mutations and uterine cancer is unclear.

42 estrogen and progesterone receptors, but in uterine cancers, it is likely no longer under control of

43 efits of minimally invasive hysterectomy for uterine cancer, population-level data describing the pro

44 ved kappa s of 0.36 and 0.25 for ovarian and uterine cancers, respectively, exceeded chance expectati

45 results suggest that clomiphene may increase uterine cancer risk (rate ratio (RR) = 1.79, 95% confide

46 Uterine cancer risk increased with clomiphene dose (RR =

47 Clomiphene may increase uterine cancer risk, with higher doses leading to higher

48 may be of concern with regard to breast and uterine cancer risk.

49 equently inactivated in brain, prostate, and uterine cancers that acts as a phosphatase on phosphatid

50 Despite the high prevalence of uterine cancers, the molecular events that lead to neopl

51 ing that longer wait times from diagnosis of uterine cancer to definitive surgery have a negative imp

52 The prevalence of uterine cancer, uterine neoplasms of uncertain malignant

53 ciated with incontinence and falls; cervical/uterine cancer was associated with falls and osteoporosi

54 Uterine cancer was identified in 73 (1 in 528) women who

55 Using a mouse model of PTEN-deficient uterine cancer, we describe a surprising inhibitory role

56 Through 1999, 39 uterine cancers were ascertained by questionnaire or can

57 dian age 45.6 (IQR: 40.9 - 52.5), 8 incident uterine cancers were observed (4.3 expected; observed to

58 database to identify women with stage I-III uterine cancer who underwent hysterectomy from 2006 to 2

59 g cancer diagnosis by 2030, and melanoma and uterine cancer will become the fifth and sixth most comm

60 rcoma, two clinically aggressive subtypes of uterine cancer with few therapeutic options.

61 There were 36 cases of uterine cancer with tamoxifen and 23 with raloxifene (RR

62 s likely to have thromboembolic sequelae and uterine cancer), women without a uterus, and women at hi